denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Biological, drug-drug interaction, Therapies, Combinations, enzyme inhibitors, Biological Processes, Clinically relevant, pathways
Hematology Disease Topics & Pathways:
Biological, drug-drug interaction, Therapies, Combinations, enzyme inhibitors, Biological Processes, Clinically relevant, pathways
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Javier Pinilla Ibarz, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute
Disclosures:
Pinilla Ibarz: Novartis: Consultancy; Abbvie: Consultancy, Speakers Bureau; Sanofi: Consultancy; TG Therapeutics: Consultancy; Sunesis Pharmaceuticals: Consultancy; Pharmacyclics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau.
Speakers:
Alexey Danilov, MD, City of Hope Comprehensive Cancer Center
,
Callie C. Coombs, MD, University of North Carolina
,
Joanna M Rhodes, MD, Northwell Health
and
Sameh Gaballa, MD, H. Lee Moffitt Cancer Center and Research Institute
Disclosures:
Danilov: Rigel Pharmaceuticals: Consultancy; Bristol-Myers Squibb: Research Funding; Karyopharm: Consultancy; Pharmacyclics: Consultancy; Celgene: Consultancy; Aptose Biosciences: Research Funding; Bayer Oncology: Consultancy, Research Funding; Takeda Oncology: Research Funding; Gilead Sciences: Research Funding; Nurix: Consultancy; TG Therapeutics: Consultancy; Genentech: Consultancy, Research Funding; BeiGene: Consultancy; Abbvie: Consultancy; Verastem Oncology: Consultancy, Research Funding; Astra Zeneca: Consultancy, Research Funding. Coombs: LOXO Oncology: Honoraria; MEI Pharma: Honoraria; AstraZeneca: Honoraria; Genentech: Honoraria; Abbvie: Consultancy, Honoraria; Novartis: Honoraria; Octapharma: Honoraria. Rhodes: AstraZeneca: Consultancy; Pharmacyclics: Consultancy; Abbvie/Genentech: Consultancy; Verastem: Consultancy.
This activity is intended to update clinicians with the latest information regarding the use of PI3K inhibitors in the treatment of hematologic malignancies, including chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, and other lymphomas. Throughout this activity, experts will review current and emerging data sets for PI3K inhibitors across hematologic malignancies, implications for clinical practice, and considerations for selecting a PI3K inhibitor for your patient. By participating in this activity, clinicians will be able to outline latest advances in PI3K inhibitors, evaluate the latest clinical data on efficacy and safety of current as well as emerging PI3K inhibitors, and make informed decisions about integrating these treatments, when approved, for best patient outcomes.
See more of: Satellite Symposia